|
Indicator: 1
[Output]
Measurements in/of Recommendations Made
Relationships: Department of Health and Human Services - Narrower_Than
Other Information:
National Cancer Institute Board of Scientific Advisors
| Type |
Target |
Actual |
| StartDate |
2010-10-01 |
2010-10-01 |
| EndDate |
2011-09-30 |
2011-09-30 |
| Number |
n/a |
138 |
| Description |
Unspecified |
1. A motion made to accept the minutes of the 46th meeting of the NCI BSA held on 28 June 2010. The motion was seconded and
approved unanimously. 2. A motion made to establish a BSA ad hoc caBIG® working group was seconded and approved unanimously.
3. A motion to concur on the reissuance of the Division of Cancer Prevention’s (DCP) request for proposal (RFP) entitled “Cancer
Preventive Agent Development Program: Preclinical Chemopreventive Agent Development Research Program” was seconded and approved
with the provision that the concept would be reviewed and presented for reissueance in 2 years. 4. A motion to concur on the
reissuance of the DCP’s request for application (RFA)/Cooperative Agreement (Coop. Agr.) entitled “Community Clinical Oncology
Program” was seconded and approved unanimously. 5. A motion to concur on the reissuance of the DCP’s RFA/Coop. Agr. entitled
“Community Clinical Oncology Program Research Bases” was seconded and approved unanimously with the request for a status report
every 2 years and reissuance concept presented every 3 years. 6. A motion to concur on the reissuance of the DCP’s RFA/Coop.
Agr. entitled “Minority-Based Community Clinical Oncology Program” was seconded and approved unanimously with the request
for a status report every 2 years and a reissuance concept presented every 3 years. 7. A motion to concur on the reissuance
of the Division of Cancer Treatment and Diagnosis’ (DCTD) RFA/Coop. Agr. entitled “Childhood Cancer Survivorship Study (CCSS)”
was seconded and approved with the provision that new treatments that may change survivorship effects be considered in research
design and annual evaluations. 8. A motion made to accept the minutes of the 47th meeting of the NCI BSA held on 1 November
2010, was seconded and approved unanimously. 9. A motion to defer concurrence on the Division of Cancer Treatment and Diagnosis’
(DCTD) request for application (RFA)/Cooperative Agreement (Coop. Agr.) entitled “National Specimen Banks To Support NCI Clinical
Trials Network” was seconded and approved unanimously. 10. A motion to concur on the Office of the Director’s RFA/Coop. Agr.
entitled “Cancer Target Discovery and Development Network Centers” was seconded and approved. 11. A motion to concur on the
reissuance of the Division of Cancer Prevention’s (DCP) RFA/Coop. Agr. entitled “Alliance of Glycobiologists for Detection
of Cancer: A Trans-NIH Program” was seconded and approved. 12. A motion made to accept the report of the BSA Cancer Bioinformatics
Grid (caBIG®) Working Group, Titled: "An Assessment of the Impact of the NCI Cancer Biomedical Informatices Grid (caBIG®),
Report of the Board of Scientific Advisors Ad Hoc Working Group" was seconded and approved unanimously. 13. A motion made
to accept the minutes of the 48th meeting of the NCI BSA held on 1 March 2011, was seconded and approved unanimously. 14.
A motion made to establish an HIV Malignancy Ad hoc Subcommittee was seconded and approved unanimously. 15. A motion made
to establish a caBIGTM Oversight Ad hoc Subcommittee was seconded and approved unanimously. 16. A motion to concur on the
Office of the Director’s (OD) request for application (RFA) entitled “Research Answers to NCI’s Provocative Questions” was
seconded and approved unanimously with the provision that challenging implementation issues will be addressed. 17. A motion
to concur on the reissuance of the Division of Cancer Control and Population Science’s (DCCPS) RFA/Coop. Agr. entitled “HMO
Cancer Research Network Research Resources” was seconded and approved unanimously. 18. A motion to concur on the reissuance
of the OD’s RFA entitled “SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics Imaging Technologies,
Interventional Devices, Diagnostics, and Prognostics Toward Commercialization” was seconded and approved unanimously.
|
|
